SPRB

Conviction 24HealthcareScan · Mon, Aug 10, 2026

SPRB$45.96-1.94%

ResistanceSupportVol 14

Vol MA14 55.51K

May 11May 28Jun 16Jul 6Jul 23Aug 10

SPRUCE BIOSCIENCES, INC.PHARMACEUTICAL PREPARATIONSwww.sprucebiosciences.com ↗

Price45.96

Change-1.94%

Gap-1.49%

Rel volume1.99×

Avg volume60.07K

Avg $ vol2.67M

SMA 2044.45

SMA 5048.43

SMA 20069.46

Price vs 50-5.11%

Price vs 200-33.84%

MA stackbearish

50/200 cross—

Supertrenddown · 50.68

RSI (14)49

MACD hist0.65

MACD crossbull · 4d

Stoch %K / %D79 / 86

ADX (14)23

+DI / −DI15 / 17

RSI divergence—

MACD divergenceBullish

ATR %+5.70%

ADR %5.46%

52w high182.60

52w low0.0786

From 52w high-74.83%

Above 52w low+58373.28%

New 52w highNo

SqueezeOff

Bollinger width15.30%

%B0.72

Donchian pos58.36%

Donchian high49.98

Donchian low40.33

AVWAP (52w high)100.71

vs AVWAP high-54.36%

AVWAP (52w low)81.59

vs AVWAP low-43.67%

OBV trendDown

Chaikin MF (20)-0.03

Today vs 20d1.99×

Avg vol (14d)55.51K

Avg vol (20d)60.07K

Avg $ vol (20d)2.67M

Market cap126.49M

RS 3m (vs SPY)-22.84%

RS 6m (vs SPY)-47.96%

RS line new highNo

Trend template1/8

Technical rank12.9

1 week+6.54%

1 month-8.21%

3 months-18.65%

6 months-36.52%

1 year+13554.19%

YTD-49.33%

P/E-3.25

P/B3.65

P/S—

P/FCF-3.80

EPS-50.83

Div yield—

ROE-112.46%

ROA-69.38%

Debt/Eq0.19

Current4.67

EV/EBITDA-2.16

Gross margin—

Net margin—

Rev growth-100.00%

EPS growth26.53%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value78.88M

Revenue0

Net income-12.27M

Gross profit—

Free cash flow-33.33M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out2.75M

Employees8

ListedFri, Oct 9, 2020

Free float722.82K

Float %67.5%

Short interest415.86K

Days to cover6.1d

Short volume66.4%

Squeeze score97 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction24 / 100

Pattern quality—

Tech rank12.9 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance56.48

Support40.89

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in SPRB

All disclosures →

No recent disclosed trades by Congress in SPRB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in SPRB · 6 buys

Insider	Side	Shares	Value	Traded	Filed
Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Common Stock · 2026-06-30	Grant	266	$1K	2026-06-30	2026-07-09
Walbert Keli Director · Stock Option (Right to Buy) · 2026-05-21	Grant	1.7K	$0	2026-05-21	2026-05-26
SIMPSON CAMILLA V Director · Stock Option (Right to Buy) · 2026-05-21	Grant	1.7K	$0	2026-05-21	2026-05-26
GREY MICHAEL G Executive Chairman · Stock Option (Right to Buy) · 2026-05-21	Grant	1.7K	$0	2026-05-21	2026-05-26
SPIEGELMAN DANIEL K Director · Stock Option (Right to Buy) · 2026-05-21	Grant	1.7K	$0	2026-05-21	2026-05-26
Barretto-Ko Percival Director · Stock Option (Right to Buy) · 2026-05-21	Grant	1.7K	$0	2026-05-21	2026-05-26

SEC filings

EDGAR filings in SPRB · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.